Unified Commitment News Today

Natalizumab treatment long after a multiple sclerosis diagnosis is associated with worse functional and brain outcomes compared with early initiation.

Patients with MS stable on natalizumab administered every 4 weeks may be able to safely switch to every-6-weeks dosing with no clinically meaningful loss of efficacy.

Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm high

Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every...

Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower